GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » EBIT

Affymax (Affymax) EBIT : $2.69 Mil (TTM As of Jun. 2014)


View and export this data going back to 2006. Start your Free Trial

What is Affymax EBIT?

Affymax's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2014 was $7.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2014 was $2.69 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Affymax's annualized ROC % for the quarter that ended in Jun. 2014 was -74.70%. Affymax's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2014 was 6,857.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


Affymax EBIT Historical Data

The historical data trend for Affymax's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax EBIT Chart

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -77.84 -13.93 -61.22 -92.00 -15.02

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.29 -1.69 -1.43 -1.39 7.21

Competitive Comparison of Affymax's EBIT

For the Biotechnology subindustry, Affymax's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Affymax's EV-to-EBIT falls into.



Affymax EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affymax  (OTCPK:AFFY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Affymax's annualized ROC % for the quarter that ended in Jun. 2014 is calculated as:

ROC % (Q: Jun. 2014 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2014 ) + Invested Capital (Q: Jun. 2014 ))/ count )
=-4.096 * ( 1 - 0% )/( (9.196 + 1.771)/ 2 )
=-4.096/5.4835
=-74.70 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2014) data.

2. Joel Greenblatt's definition of Return on Capital:

Affymax's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2014 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2014 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2014  Q: Jun. 2014
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=28.836/( ( (0 + max(-8.199, 0)) + (0 + max(0.841, 0)) )/ 2 )
=28.836/( ( 0 + 0.841 )/ 2 )
=28.836/0.4205
=6,857.55 %

where Working Capital is:

Working Capital(Q: Mar. 2014 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.6) - (0.61 + 0 + 8.189)
=-8.199

Working Capital(Q: Jun. 2014 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.055) - (0.214 + 0 + 0)
=0.841

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2014) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Affymax's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2014 )
=2.694/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affymax EBIT Related Terms

Thank you for viewing the detailed overview of Affymax's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax (Affymax) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson officer: Chief Financial Officer 8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp officer: Chief Commercial Officer 4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte director
Karin L Walker officer: VP, Finance & CAO C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton director
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland officer: EVP, Corp. Development and CFO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris director, officer: CEO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor 05-13-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor 09-30-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor 05-19-2010